ZIMLAB Stock Overview
Engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
ZIM Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹82.74 |
| 52 Week High | ₹128.90 |
| 52 Week Low | ₹79.49 |
| Beta | 0.51 |
| 1 Month Change | -3.77% |
| 3 Month Change | -22.47% |
| 1 Year Change | -28.08% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -26.21% |
Recent News & Updates
Recent updates
ZIM Laboratories (NSE:ZIMLAB) Has A Somewhat Strained Balance Sheet
Nov 14
ZIM Laboratories' (NSE:ZIMLAB) Anemic Earnings Might Be Worse Than You Think
May 21Earnings Not Telling The Story For ZIM Laboratories Limited (NSE:ZIMLAB) After Shares Rise 28%
Apr 26ZIM Laboratories Limited's (NSE:ZIMLAB) Shares May Have Run Too Fast Too Soon
Feb 20Estimating The Fair Value Of ZIM Laboratories Limited (NSE:ZIMLAB)
May 16Sentiment Still Eluding ZIM Laboratories Limited (NSE:ZIMLAB)
Nov 29Shareholder Returns
| ZIMLAB | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -4.0% | -2.4% | -1.6% |
| 1Y | -28.1% | 12.4% | 1.7% |
Return vs Industry: ZIMLAB underperformed the Indian Pharmaceuticals industry which returned 13.9% over the past year.
Return vs Market: ZIMLAB underperformed the Indian Market which returned 3.1% over the past year.
Price Volatility
| ZIMLAB volatility | |
|---|---|
| ZIMLAB Average Weekly Movement | 5.6% |
| Pharmaceuticals Industry Average Movement | 7.3% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in IN Market | 9.9% |
| 10% least volatile stocks in IN Market | 4.8% |
Stable Share Price: ZIMLAB has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: ZIMLAB's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 556 | Chandrashekhar Mainde | www.zimlab.in |
ZIM Laboratories Limited engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally. The company provides its products in pre- formulation intermediates and finished formulations in the oral solid dosage forms, such as pellets, taste-masked powders, granules, tablets, capsules, dry syrup, and oral thin films. It offers therapeutics in the areas of urology, gastroenterology, antibiotics, anti-infectives, cardiovascular, central nervous system, NSAIDs/pain analgesics, and vitamins and supplements.
ZIM Laboratories Limited Fundamentals Summary
| ZIMLAB fundamental statistics | |
|---|---|
| Market cap | ₹4.04b |
| Earnings (TTM) | ₹153.66m |
| Revenue (TTM) | ₹3.88b |
26.3x
P/E Ratio1.0x
P/S RatioIs ZIMLAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZIMLAB income statement (TTM) | |
|---|---|
| Revenue | ₹3.88b |
| Cost of Revenue | ₹1.86b |
| Gross Profit | ₹2.02b |
| Other Expenses | ₹1.87b |
| Earnings | ₹153.66m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.15 |
| Gross Margin | 52.12% |
| Net Profit Margin | 3.96% |
| Debt/Equity Ratio | 41.5% |
How did ZIMLAB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/09 02:05 |
| End of Day Share Price | 2025/05/09 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ZIM Laboratories Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.